 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Feb 26 Calls Today's Calls |
| Call Details | |||
| CV Therapeutics Earnings Conference Call (Q4 2007) Tue, Feb 26, 2008, 5:00 pm Eastern
| |||
| About CV Therapeutics (NasdaqGM:CVTX) | |||
| CV Therapeutics, Inc., a biopharmaceutical company, focuses on applying molecular cardiology to the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its approved product, Ranexa (ranolazine extended-release tablets) is indicated for the treatment of chronic angina. The company also develops Ranexa, which is in Phase III clinical development stage for the treatment of acute coronary syndrome. In addition, it has other clinical and preclinical drug development candidates and programs, including Regadenoson, which is in Phase III clinical development stage for use as a pharmacologic stress agent in myocardial perfusion imaging studies; Tecadenoson, a selective A1-adenosine receptor agonist for the reduction of rapid heart rate during acute atrial arrhythmias, which is in Phase III clinical development stage; Adentri, which is in Phase II clinical development stage for the treatment of heart failure; and CVT-6883 that is in Phase I clinical development stage for the treatment of cardiopulmonary disease. Further, the company’s preclinical drug development candidates and programs include Adenosine receptors for atrial arrhythmias, lipid metabolism, diabetes, metabolic syndrome, dyslipidemia, and addiction; Late sodium current for ischemic conditions; and reverse cholesterol transport for atherosclerosis. CV Therapeutics has strategic alliances with Roche Palo Alto LLC; Biogen Idec, Inc.; Astellas Pharma, Inc.; and PTC Therapeutics, Inc. The company was founded in 1990 and is headquartered in Palo Alto, California. | |||
More Info: | |||
